{
  "CitationSubset": [],
  "KeywordList": [
    [
      "COVID-19",
      "SARS-CoV-2",
      "computational docking",
      "genomics characterization",
      "in silico"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "34889898",
  "DateCompleted": {
    "Year": "2021",
    "Month": "12",
    "Day": "22"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "07",
    "Day": "16"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2021",
        "Month": "11",
        "Day": "16"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.3390/cimb43030140"
    ],
    "Journal": {
      "ISSN": "1467-3045",
      "JournalIssue": {
        "Volume": "43",
        "Issue": "3",
        "PubDate": {
          "Year": "2021",
          "Month": "Nov",
          "Day": "16"
        }
      },
      "Title": "Current issues in molecular biology",
      "ISOAbbreviation": "Curr Issues Mol Biol"
    },
    "ArticleTitle": "A Comparative Study between Spanish and British SARS-CoV-2 Variants.",
    "Pagination": {
      "StartPage": "2036",
      "EndPage": "2047",
      "MedlinePgn": "2036-2047"
    },
    "Abstract": {
      "AbstractText": [
        "The study of the interaction between the SARS-CoV-2 spike protein and the angiotensin-converting enzyme 2 (ACE2) receptor is key to understanding binding affinity and stability. In the present report, we sought to investigate the differences between two already sequenced genome variants (Spanish and British) of SARS-CoV-2. <b>Methods:</b> In silico model evaluating the homology, identity and similarity in the genome sequence and the structure and alignment of the predictive spike by computational docking methods. <b>Results:</b> The identity results between the Spanish and British variants of the Spike protein were 28.67%. This close correspondence in the results between the Spanish and British SARS-CoV-2 variants shows that they are very similar (99.99%). The alignment obtained results in four deletions. There were 23 nucleotide substitutions also predicted which could affect the functionality of the proteins produced from this sequence. The interaction between the binding receptor domain from the spike protein and the ACE2 receptor produces some of the mutations found and, therefore, the energy of this ligand varies. However, the estimated antigenicity of the British variant is higher than its Spanish counterpart. <b>Conclusions:</b> Our results indicate that minimal mutations could interfere in the infectivity of the virus due to changes in the fitness between host cell recognition and interaction proteins. In particular, the N501Y substitution, situated in the RBD of the spike of the British variant, might be the reason for its extraordinary infective potential."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [
          "0000-0001-9531-6654"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Research Group on Electronic Technology and Industrial Computing (TIC-150), Department of Artificial Intelligence, University of Seville, 41013 Sevilla, Spain."
          }
        ],
        "LastName": "Jimenez Ruiz",
        "ForeName": "Jose A",
        "Initials": "JA"
      },
      {
        "Identifier": [
          "0000-0003-4966-5938"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Unidad M\u00e9dico-Quir\u00fargica de Enfermedades Respiratorias, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Roc\u00edo/Universidad de Sevilla, 41013 Sevilla, Spain."
          },
          {
            "Identifier": [],
            "Affiliation": "Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, 28029 Madrid, Spain."
          }
        ],
        "LastName": "Lopez Ramirez",
        "ForeName": "Cecilia",
        "Initials": "C"
      },
      {
        "Identifier": [
          "0000-0003-1703-1367"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Unidad M\u00e9dico-Quir\u00fargica de Enfermedades Respiratorias, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Roc\u00edo/Universidad de Sevilla, 41013 Sevilla, Spain."
          },
          {
            "Identifier": [],
            "Affiliation": "Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, 28029 Madrid, Spain."
          }
        ],
        "LastName": "Lopez-Campos",
        "ForeName": "Jose Luis",
        "Initials": "JL"
      }
    ],
    "PublicationTypeList": [
      "Comparative Study",
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Switzerland",
    "MedlineTA": "Curr Issues Mol Biol",
    "NlmUniqueID": "100931761",
    "ISSNLinking": "1467-3037"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Spike Glycoprotein, Coronavirus"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "spike protein, SARS-CoV-2"
    },
    {
      "RegistryNumber": "EC 3.4.17.23",
      "NameOfSubstance": "ACE2 protein, human"
    },
    {
      "RegistryNumber": "EC 3.4.17.23",
      "NameOfSubstance": "Angiotensin-Converting Enzyme 2"
    }
  ],
  "SupplMeshList": [
    "SARS-CoV-2 variants"
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Amino Acid Sequence"
    },
    {
      "QualifierName": [
        "metabolism"
      ],
      "DescriptorName": "Angiotensin-Converting Enzyme 2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Base Sequence"
    },
    {
      "QualifierName": [
        "epidemiology",
        "metabolism",
        "pathology",
        "virology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Computational Biology"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Protein Binding"
    },
    {
      "QualifierName": [
        "genetics",
        "isolation & purification",
        "metabolism",
        "physiology"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Sequence Alignment"
    },
    {
      "QualifierName": [
        "epidemiology"
      ],
      "DescriptorName": "Spain"
    },
    {
      "QualifierName": [
        "genetics",
        "metabolism"
      ],
      "DescriptorName": "Spike Glycoprotein, Coronavirus"
    },
    {
      "QualifierName": [
        "epidemiology"
      ],
      "DescriptorName": "United Kingdom"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Virus Internalization"
    }
  ],
  "CoiStatement": "J.L.L.C. has received honoraria during the last three years for lecturing, scientific advice, participation in clinical studies or writing for publications for (alphabetical order): AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, Esteve, Ferrer, Gebro, GlaxoSmithKline, Grifols, Menarini, Megalabs, Novartis and Rovi. The rest of the authors declare no conflicts of interest."
}